医学信息2019，Vol.32Issue(4)：104-106,3.DOI:10.3969/j.issn.1006-1959.2019.04.033
Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析
Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer
黄雨 1楼浩男 2涂刚1
作者信息
- 1. 重庆医科大学附属第一医院内分泌乳腺外科,重庆 400016
- 2. 重庆医科大学附属第一医院血管外科,重庆 400016
- 折叠
摘要
Abstract
Objective To investigate the efficacy and influencing factors of neoadjuvant chemotherapy for Luminal B breast cancer. Methods The clinical medical records of 81 patients with Luminal B breast cancer who underwent 4 TEC regimen neoadjuvant chemotherapy in our hospital from January 2016 to June 2018 were retrospectively analyzed. The clinicopathological features and related indicators were analyzed. Correlation of efficacy. Results The p CR rate of neoadjuvant chemotherapy was 4.94％. The clinical efficacy and clinical stage were statistically significant (P<0.05). Whether pCR and age, BMI, menopausal status, primary tumor size, tumor location, and lymph node status at diagnosis were obtained. There were no significant differences in PR, P53 and Ki67 (P>0.05). Except for 4 patients with p CR, the expression of ER and PR and the Ki67 index of77 patients with breast cancer before and after neoadjuvant chemotherapy were statistically significant (P <0.05). Conclusion Neoadjuvant chemotherapy is relatively ineffective in patients with late clinical stage. Ki67 may be a predictor of neoadjuvant chemotherapy for breast cancer.关键词
乳腺肿瘤/Luminal B/新辅助化疗/病理完全缓解/影响因素Key words
Breast neoplasms/Luminal B/Neoadjuvant chemotherapy/Pathological complete remission/Influencing factors分类
医药卫生引用本文复制引用
黄雨,楼浩男,涂刚..Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析[J].医学信息,2019,32(4):104-106,3.
